Table 2 Individual study results. Descriptive data, Mean and standard deviation for adult height and net height gain
Study | Sample size | Mean age baseline yrs (SD) | Mean BA baseline yrs (SD) | Mean MPH | Intervention | Dose of Ox (mg/kg/day) | Mean time on Ox yrs | Mean AH cm (SD) | Mean Ht gain Cm (SD) | Age at estrogen initiation Yrs (SD) | Puberty Sp (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Menke [33] | 42 | 8.5 (4.0) | 8.1 (3.6) | NR | GH + Ox | 0.03 | 6 | 156.7 (7.2) | 9.5 (4.7) | 12.8 (0.9) | 21 |
36 | 9.1 (3.5) | 8.8 (3.4) | NR | GH + Ox | 0.06 | 6 | 156.5 (5.8) | 8.3 (4.7) | 12.7 (0.9) | 24 | |
42 | 9.4 (3.8) | 9.0 (3.4) | NR | GH + Placebo | - | 155.6 (5.4) | 7.2 (4) | 12.9 (1.0) | 25 | ||
Gault [34] | 47 | 10.2 (1.1) | NR | NR | GH + Ox | 0.05 | 5 | 151.06 (4.53) | - | 12 (N = 12) 14 (N = 24) | 23 |
52 | 10.3 (0.9) | NR | NR | GH + Placebo | - | 149.72 (6.75) | - | 12 (N = 17) 14 (N = 28) | 13 | ||
Rosenfeld [3] | 45 | 9.9 (2.3) | 8 | 162.5 (4.1) | GH + Ox | 0.125a | 6 | 152.1 (5.9) | 10.3 (4.7) | 14.9 (0.9) | NR |
17 | 9.1 (2.1) | 8 | 164.5 (3.7) | GH + Placebo | - | 150.4 (5.5) | 8.4 (4.5) | 15.2 (0.9) | NR | ||
Stahnke [35] | 33 | 11.8 (2.0) | 9.9 (1.0) | 166.9 (4.0) | GH + Ox | 0.1b | 4 | 155.1 (4.5) | 7.9 (3.8) | 14.9 | NR |
38 | 11.7 (1.8) | 9.9 (1.1) | 163.6 (4.4) | GH + Ox | 0.1c | - | 152.8 (3.8) | 6.4 (3.5) | 14.9 | NR | |
20 | 11.5 (1.2) | 10.3 (0.5) | 165.1 (5.5) | GH + Placebo | - | 151.7 (3.1) | 3.6 (2.6) | 14.9 | NR |